Temasek and Yunfeng Capital Lead Series B Round in WuXi NextCODE

Institutional capital is investing more of its resources into genome sequencing data companies, betting on the advent of precision medicine. WuXi NextCODE, a contract genomics organization, raised US$ 75 million in a Series B round. The financing round was led by Singapore’s Temasek Holdings and Yunfeng Capital, a fund backed by Alibaba founder Jack Ma. Other investors in the round include Amgen Ventures, the corporate venture unit of Amgen Inc., and 3W Partners, a private equity firm focused on China cross-border investments. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]



Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute


 
institutional investor investment mandates